Citations

Clear

1422 citation(s) found for "Sn, Huang".

Real‐World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma ( RRMM ): An International Myeloma Working Group Immunotherapy Registry Real‐World Analysis
Janakiram, Murali , Tan, C. R., Mian, Hira, Huang, C Y, Popat, Rakesh , Martínez‐Lopez, Joaquín, Kastritis, Efsthathios, Chng, Wee-Joo, Kapoor, Prashant , Dave, Mrugakshi, Bal, Susan, Garderet, Laurent, Corraes, Andre De Menezes Silva , Riedhammer, Christine , Steinbrunn, Torsten, Nagarajan, Chandramouli, Einsele, Hermann, Martin, T, Krishnan, Amrita, Lin, Yi, Martínez‐López, Joaquín , Frigault, Matthew J. , Larrea, Carlos Fernández de , Mian, Hira , Tan, Carlyn R , Kastritis, Efstathios , Corona, Magdalene , Martinez-Lopez, Joaquin , Mian, Hira , Janakiram, Murali , Tan, Carlyn , Popat, Rakesh , Chng, Wee Joo , Bal, Susan , Garderet, Laurent , Steinbrunn, Torsten , Nagarajan, Chandramouli

Mayo Clinic

American Journal of Hematology | May 20, 2026 | Volume: 101 | Issue: 8 | Pages: 1928-1937

10.1002/ajh.70376 | PMID 42157444 Get It

ABSTRACT Talquetamab is a GPRC5D × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). This is the first real‐world study to comprehensively report muco‐cutaneous toxicities, infections, and efficacy of talquetamab in 151 patients across five countries with the longest follow‐up reported enabling better efficacy and toxicity estimates. The median age was 64 years; high‐risk cytogenetics were present in 42%; ECOG ≥ 2 in 22%; 12% had creatinine clearance < 30; and 55% would not have met MonumenTAL‐1 eligibility. Patients received a median of 6 prior lines of therapy, 53% were penta‐refractory, and 75% received prior BCMA therapy. Talquetamab was associated with skin toxicity in 39.7%, nail toxicity in 75.5%, dysgeusia in 60.4%, and oral toxicities in 62.9%, with grade ≥ 3 events uncommon (≤ 4%) and dose interruptions infrequent (9.6% for skin toxicity, 6.9% for dysgeusia, and 4.0% for oral toxicities). These findings underscore the need for improved supportive care for muco‐cutaneous toxicities. In multivariate analysis, only platelet count < 50 (HR 1.8, 95% CI 1.15–2.83) was associated with inferior PFS, while penta‐refractory status, absolute lymphocyte count < 0.4, and prior BCMA‐targeted therapy were not statistically significant. With a median follow‐up of 12.7 months, the overall response rate was 67.6%, median progression‐free survival was 7 months, and 12‐month overall survival was 65%. This study shows that talquetamab efficacy is maintained in a heavily pretreated real‐world population with high prior BCMA exposure and notable comorbidity burden.
Resolving inflammatory bowel disease risk variants to genes and cell types
Zhang, Rui, Gettler, Kyle , Haritunians, Talin , Cleynen, Isabelle , Stevens, Christine R , Zhang, Qian , Tastad, Christopher, Medici, Catalina, Abreu, María T. , Achkar, Jean-Paul, Ahmad, Tariq, Bernstein, Charles, Brooks, Johanne , Bujanda, Luis, Butterworth, Jeffrey, Clark, Katie, Cummings, F, Buono, Joanne Del, Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Jarvis, Mark , Johnston, EL, Kemp, Cheryl, Kennedy, Nick, Lewis, James D. , Li, Andy, Louis, Édouard , Moayyedi, Paul, Moran, G , Newman, Bill, Oglesby, Arabis, Pekow, Joel, Perez, Kate J., Pollok, R, Radford-Smith, Graham , Raffals, L, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Reinisch, Walter , Satsangi, Jack, Selinger, Christian, Shedwell, Sophy, Silverberg, Mark S. , Singh, Salil, Steel, Alan, Uhlig, Holm H. , Verma, Ajay, Weersma, Rinse K. , Xavier, Ramnik, Parkes, M, Lee, James C. , McGovern, D, Anderson, Carl A. , Lee, James , Raine, Tim , Zhang, Rui , Haritunians, Talin , Raine, Tim , Anderson, Carl A , Fachal, Laura , Cleynen, Isabelle , Stevens, Christine R. , Zhang, Qian , Tastad, Christopher , Do, Ron , Achkar, Jean–Paul , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , D’Amato, Mauro , Duerr, Richard H , Ellinghaus, David , Franchimont, Denis , Franke, André , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Julià, Antonio , Kennedy, Nicholas Alexander , Kupcinskas, Juozas , Latiano, Anna , Lewis, James D , McLaughlin, John , Moayyedi, Paul , Mowat, Craig , Newberry, Rodney D. , Perez, Kate J, Prescott, Natalie , Radford‐Smith, Graham L , Raffals, Laura E. , Reinisch, Walter , Rogler, Gerhard , Sands, Bruce E , Satsangi, Jack, Scharl, Michael , Schreiber, Stefan , Sebastian, Shaji , Selinger, Christian P. , Steed, Helen , Vermeire, Séverine , Halfvarson, Jonas , Daly, Mark J. , Lamb, Christopher A , Huang, Hailiang , McGovern, Dermot P.B. , Rioux, John D. , Cho, Judy H , Zhang, Rui

Mayo Clinic

No container title available | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26352926 Get It

Abstract Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
C101-10 Epigenetic Signatures of Sputum Eosinophils in COPD
Cao, S, Bleecker, E R, Meyers, D A, Zein, J G, Shrivastav, A, Chen, X, Hawkins, G A, Barjaktarevic, I, Bowes, R, Barr, R G, Comellas, A P, Cooper, C B, Couper, D, Han, M K, Hansel, N N, Hastie, A T, Kaner, R J, Kanner, R E, Martinez, F J, O’Neal, W K, Paine, R, Woodruff, P G, Christenson, S A, Curtis, J L, Huang, Y J , Ortega, V E, Comellas, Alejandro P. , Comellas, Alejandro P , Meyers, Deborah A. , Zein, Joe , Barr, R. Graham , Han, MeiLan King , Hansel, Nadia N. , Hastie, Annette T. , Kaner, R.J. , Kanner, R.E., O’Neal, Wanda K. , Curtis, Jeffrey L.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2029 Get It

Abstract Rationale Eosinophilic airway inflammation in COPD is associated with more frequent exacerbations,lower lung function,and corticosteroid responsiveness.DNA methylation captures information about genetic factors and environmental exposures, but is under-studied in eosinophilic COPD.We hypothesized that sputum cell methylation patterns reflect genomic regulation of inflammatory endotypes in COPD by DNA sequence variation. Methods We analyzed DNA previously extracted from induced sputum cells for a prior study(PMID38261629) for which sufficient quantity DNA remained for methylation arrays.For this analysis,we focused on n = 132 SPIROMICS participants with ≥20 pack-years smoking history.Samples were stratified into tertiles based on sputum eosinophil proportions,previously determined from sputum cell differential analysis by the centralized sputum analysis core for SPIROMICS(Univ of North Carolina).We assessed proportion of DNA methylation (β values) spanning 936,866 CpG sites using the Illumina Infinium Methylation EPICv2.0 BeadChip Array,which we transformed into M values(meffil R package). To identify differentially methylated regions (DMRs)(FDR&lt;0.05 in minimum of 2 CpG sites per gene region),we contrasted CpG β values between the high-eosinophil and low-eosinophil tertiles(N = 44 each),using the DMRcate package.We tested for enrichment of genes overlapping with significant DMRs using Enrichr (GWAS Catalog 2025 gene set library).To identify genetic variants associated with DNA methylation levels,we performed Methylation Quantitative Trait Loci (meQTL) analysis using TensorQTL.For each CpG site,we tested associations with SNPs within a ± 500 kb window (cis-meQTL).The linear regression model included age,sex,BMI,smoking status,smoking pack-years,study site,inhaled corticosteroid use, the first two genetic principal components, cell-type proportions (macrophages/monocytes, neutrophils, squamous epithelial cells, lymphocytes), and eosinophil tertile . Significant meQTLs were identified at an FDR&lt;0.05 using Benjamini-Hochberg correction. Results A total of 532 eosinophil-associated DMRs (FDR &lt; 0.05) were identified between the high- and low-eosinophil groups,encompassing 446 unique genes.The top enriched pathways related to counts of eosinophils (adjusted p = 0. 00002464), lymphocytes (adjusted p = 0.0001860), and the sum of eosinophils-plus-basophils (adjusted p = 0.0001860).We identified 18,432 significant SNP-CpG/meQTL pairs (FDR &lt; 0.05),suggesting extensive genetic influence on airway DNA methylation patterns.Among the n = 521 eosinophil-associated CpGs that overlapped with meQTLs,rs55687040 (TENT2,a gene involved in mRNA and miRNA processing) is a GWAS locus for FEV1/FVC ratio (PMID: 26634245), suggesting possible genetic control of airway eosinophilic methylation signatures. Conclusions Our findings disclose distinct DNA methylation signatures associated with sputum eosinophil proportion in COPD.A subset of these CpGs are regulated by genetic variants,suggesting an integrated genetic-epigenetic mechanism underlying airway eosinophilic inflammation with the potential to influence COPD risk and severity. This abstract is funded by: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880, U24 HL141762, R01 HL182622, and R01 HL144718), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from Amgen; AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; Genentech; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; MGC Diagnostics; Novartis Pharmaceuticals Corporation; Nycomed GmbH; Polarean; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan/Viatris.
C33-05 Feature Importance Statistics Reveal Gina 2025-aligned Predictors of Asthma Exacerbations in U.S. Adults: A Cross-sectional Machine-learning Study Using Nhanes 2017-2020
Huang, S, Su, J, Huang, A

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.564 Get It

Abstract Rationale Asthma exacerbations remain a leading cause of emergency visits and impaired quality of life. The 2025 Global Initiative for Asthma (GINA) report emphasizes early identification of Type 2 inflammation, treatable traits, and comorbidities to prevent attacks. Machine learning (ML) was applied to population level data to uncover complex, nonlinear relationships between biomarkers, lifestyle factors, and exacerbation risk. This study aimed to identify key predictors of asthma exacerbations using explainable ML techniques and to interpret these predictors through the lens of GINA 2025 guidelines. Methods A cross-sectional analysis was performed using the National Health and Nutrition Examination Surveys (NHANES) 2017-2020. Adults aged ≥18 years with available asthma history and laboratory data (n = 7,922) were included. The outcome was self-reported asthma exacerbation within the past 12 months. Univariable logistic regression was used to preselect covariates from 680 demographic, dietary, laboratory, and anthropometric variables using a significance threshold of p &lt; 0.0001. Selected covariates were then entered into an XGBoost classifier. Model discrimination was assessed by the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Feature importance was ranked by the Gain metric, and Shapley Additive Explanations (SHAP) were applied to improve interpretability and align results with GINA 2025 clinical domains. Results The final model included 55 covariates and achieved an AUROC of 0.737, sensitivity of 0.960, and NPV of 0.967 for predicting exacerbations. The most influential features were octanoic acid intake, eosinophil percentage, hip circumference, standing height, and high-sensitivity C-reactive protein (hs-CRP). Individuals reporting exacerbations had higher eosinophil percentages (3.36% vs. 2.76%), larger hip circumference (115.2 cm vs. 107.2 cm), and higher hs-CRP (6.08 vs. 4.00 mg/L). These findings correspond to GINA 2025’s emphasis on eosinophils as biomarkers for anti-inflammatory therapy, systemic inflammation as a treatable trait, and obesity as a modifiable risk factor for symptom control and exacerbation prevention. Conclusion Explainable ML applied to NHANES data accurately identified physiologic and inflammatory predictors of asthma exacerbations that mirror the GINA 2025 framework. Eosinophil levels, systemic inflammation, and adiposity emerged as key treatable traits linked to exacerbation risk. These findings demonstrate the utility of ML in translating population-level data into actionable insights consistent with GINA 2025’s strategy for individualized, inflammation-guided asthma management. This abstract is funded by: None
How to Innovate as an Anesthesiologist: Guidance From the American Society of Anesthesiologists Committee on Innovation
Rens, Neil , Smischney, Nathan J. , Huang, Jiapeng , Ma, Haobo , Saffary, Roya , Arekapudi, Smitha, Pearl, Ronald G. , Rens, Neil E , Smischney, Nathan J , Huang, Jiapeng , Arekapudi, Smitha

Mayo Clinic

Anesthesia & Analgesia | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000008075 | PMID 42148767 Get It

While the field of anesthesiology has a storied history of innovation, especially related to patient safety, contemporary anesthesiologists face growing barriers to innovation from complex regulatory requirements and financial constraints. The Biodesign framework offers a systematic approach to medical technology development that can be applied to the perioperative space to address these challenges. This process begins with identification and screening of high-value clinical needs, followed by generation and evaluation of potential solutions, and culminates in strategy development, business planning, and fundraising. Each stage is designed to guide clinicians from early observation through translation into viable technologies. By adopting this structured method, anesthesiologists are well-positioned to transform clinical insights into scalable solutions, ensuring the specialty continues to advance patient safety and care in the face of evolving clinical demands.
Plasma Extracellular Vesicle Proteomics Reflects Graded Inflammation within the COCA Classification Framework for Chronic Pancreatitis
Wang, Heru, Zhang, Di , Li, Jiayu, Huang, Haojie, Ji, Baoan , Wang, Lixiang , Huang, Haojie

Mayo Clinic

Pancreas | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mpa.0000000000002675 | PMID 42148490 Get It

Fast 3-D Ultrasound Localization Microscopy via Projection-Based Processing Framework
Zhang, Jingke , Yin, Jingyi , Huang, Lijie , DeRuiter, Ryan M. , Ji, Kaipeng , Zhao, Yanzhe , Krier, James D., Zhu, Xiang, Lerman, Lilach O. , Yin, Jingyi , Zhang, Jingke , DeRuiter, Ryan , Lok, U‐Wai , Wu, Tao , Ji, Kaipeng, Huang, Chengwu , Chen, Shigao

Mayo Clinic

IEEE Transactions on Medical Imaging | May 15, 2026 | Volume: 45 | Issue: 7 | Pages: 4105-4122

10.1109/tmi.2026.3692792 | PMID 42139135 Get It

Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast Cancer
Ku, Wen‐Hui, Lin, Chia-Jen, Wu, Bogang, Wu, H. , Yen, Tzu‐Chun, Lo, Chiao , Wang, Ming-Yang, Huang, Chiun-Sheng, Lin, Po‐Han , Lien, Huang‐Chun , Tsai, Li‐Wei , Wang, Ming-Yang, Kuo, Sung‐Hsin , Huang, Chiun‐Sheng

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9236222/v1 Get It

Abstract Neoadjuvant therapy (NAT) with HER2-targeted agents is the standard treatment for patients with HER2-positive early breast cancer (HER2 + EBC). Although high levels of tumor-infiltrating lymphocytes (TILs) are associated with higher pathologic complete response (pCR) rates and improved recurrence-free survival (RFS), the specific immune components responsible remain unclear. In this study, pretreatment tumor biopsies from 188 patients receiving HER2-targeted NAT were analyzed. Univariate analysis revealed that enrichment of TIL-B cells in tumors, high HER2 mRNA and low ESR1 mRNA expression were linked to pCR (both p < 0.01). Multivariate analysis confirmed TIL-B-cell enrichment as an independent predictor of pCR. Mature IgD/IgM-high B cells, but not immature RAG1 + B cells, independently predicted pCR. Transcriptomic profiling identified 265 upregulated genes in pCR tumors enriched in MHC class II antigen presentation pathways. Immunofluorescence demonstrated increased spatial interaction of mature B cells with CD4 + T cells in pCR tumors, consistent with active antigen presentation. The antigen presenting B-cell signature, integrated mature B-cell and MHC II profile, was the strongest independent predictor of pCR (OR = 3.008, 95% CI: 1.196–7.544, p = 0.019) and was also significantly associated with improved RFS (HR = 0.109, 95% CI: 0.014–0.872), highlighting B-cell–mediated antigen presentation as a clinically relevant biomarker in HER2 + EBC.
Exome sequencing directly implicates 68 genes in inflammatory bowel disease
Zhu, Ruifei , Zhang, Qian , Yuan, Kai , Zhang, Rui , Turvey, Alexandra K. , Stevens, Christine R , Ahmad, Tariq, Bernstein, Çharles N. , Bokemeyer, Bernd , Brooks, Johanne , Butterworth, Jeffrey, Clark, Katie, Cummings, F, Ennis, Sarah, Färkkilä, M, Faubion, William A. , Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Irving, Peter, Jarvis, Mark , Johnston, EL, Karlson, Elizabeth W, Kemp, Cheryl, Kennedy, Nick, Lees, Charlie, Lewis, James D. , Li, Andy, Louis, Édouard , McGovern, Dermot P.B., Oglesby, Arabis, Perez, Kate J, Pollok, R, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Sands, Bruce, Satsangi, Jack, Schreiber, Stefan, Selinger, Christian, Shedwell, Sophy, Silverberg, M, Singh, Salil, Steel, Alan, Uhlig, H, Verma, Ajay, Vermeire, Séverine , Weersma, Rinse K. , Xavier, Ramnik, Parkes, Miles, Rioux, John D. , Anderson, Carl A. , Raine, Tim , Uhlig, Holm H. , Fachal, Laura , Bernstein, Charles Noah , Bokemeyer, Bernd , Brant, Steven R , Cho, Judy H , Duerr, Richard H , Faubion, William , Franchimont, Denis , Franke, André , Kupcinskas, Juozas , Lamb, Christopher A , Lewis, James D , Loescher, Britt-Sabina , Louis, Edouard , McCauley, Jacob L , Moayyedi, Paul , Newberry, Rodney D , Palotie, Aarno V. , Pekow, Joel , Prescott, Natalie , Sabic, Ksenija , Sands, Bruce E , Silverberg, Mark S , Sokol, Harry , Vermeire, Séverine , Weersma, Rinse K , Xavier, Ramnik J , Yu, Mingrui , Rioux, John D , Daly, Mark J. , Huang, Hailiang , Anderson, Carl A , Raine, Tim , Zhang, Qian , Yuan, Kai , Stevens, Christine R. , Fachal, Laura , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , Ennis, Sarah A. , Färkkilâ, Martti , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Karlson, Elizabeth W. , Kennedy, Nicholas Alexander , Lees, Charlie W. , McCauley, Jacob L. , McGovern, Dermot P.B. , McLaughlin, John , Moayyedi, Paul , Moran, G , Newberry, Rodney D. , Pekow, Joel , Satsangi, Jack, Sazonovs, Aleksejs , Schreiber, Stefan , Selinger, Christian P. , Steed, Helen , Parkes, Miles , Zhang, Rui

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.08.26352648 | PMID 42180385 Get It

Abstract Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
Comparison of Conventional versus Abbreviated MR Enterography: Assessing Disease Activity and Complications in Crohn Disease
Rimola, Jordi , Anupindi, Sudha, Capozzi, Nunzia , Dane, Bari, Flicek, Kristina T. , Fernández-Clotet, Agnès , Grajo, Joseph R. , Huang, Chenchan , Jaffe, Tracy A. , Ordás, I, Roca, Andreu, Saavedra, Carolina, Anupindi, Sudha A , Dane, Bari , Jaffe, Tracy , De Kock, Isabelle , Ordás, Ingrid , Radmard, Amir Reza , Roca, Andreu , Scharitzer, Martina , Dillman, Jonathan R , Rimola, Jordi , Anupindi, Sudha A. , Fernandez-Clotet, Agnes , Grajo, Joseph R. , Ordás, Íngrid , Radmard, Amir Reza

Mayo Clinic

Radiology | May 12, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252039 | PMID 42117993 Get It

In participants with Crohn disease (CD), an abbreviated MR enterography (MRE) protocol demonstrated similar interreader agreement to contrast-enhanced MRE and high intrareader concordance for detecting active CD and related complications.